Design and Synthesis of Naltrexone-Derived Affinity Labels with Nonequilibrium Opioid Agonist and Antagonist Activities. Evidence for the Existence of Different μ Receptor Subtypes in Different Tissues

L. M. Sayre, D. L. Larson, A. E. Takemori, Philip S Portoghese

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

A series of β-funaltrexamine (2, β-FNA) analogues (3-14) were synthesized that contain a variety of electrophilic groups attached at the 6/3-position of the opiate. The opioid agonist and antagonist activities of these ligands were evaluated in the guinea pig ileum (GPI) and mouse vas deferens (MVD) in vitro assays. Several of the compounds behaved like β-FNA in that they exhibited reversible agonist activity at k opioid receptors and irreversible antagonist activity at p opioid receptors. The rank order of irreversible antagonism for a series of related Michael acceptors did not parallel their intrinsic chemical reactivity, confirming that the degree of covalent binding is in part dependent on the spatial disposition of the electrophilic center relative to the receptor nucleophile (secondary recognition). The maleimidoacetamide 8 behaved very differently from β-FNA in that it exhibited considerably greater irreversible μ antagonism in MVD relative to the p blockage in the GPI. This suggests that different proportions of p receptor subtypes exist in the two tissues. Several of the agents tested, including some nonreactive control compounds, displayed an unusual type of persistent k agonist activity in the GPI. This activity, which was reversed by addition of naloxone, reappeared upon washing. Receptor models have been presented to explain this effect. A few of the reactive ligands displayed a true nonreversible k agonist activity, suggesting a covalent association with the receptor. Of note in this regard was the propiolamide 6, which appeared to be an irreversible mixed agonist-antagonist at k and μ receptors.

Original languageEnglish (US)
Pages (from-to)1325-1335
Number of pages11
JournalJournal of Medicinal Chemistry
Volume27
Issue number10
DOIs
StatePublished - Jan 1 1984

Fingerprint

Affinity Labels
Naltrexone
Narcotic Antagonists
Ileum
Guinea Pigs
Vas Deferens
Opiate Alkaloids
Ligands
Opioid Receptors
Naloxone

Cite this

@article{348b0c6ea4e64e778d7d41c5173a8b7f,
title = "Design and Synthesis of Naltrexone-Derived Affinity Labels with Nonequilibrium Opioid Agonist and Antagonist Activities. Evidence for the Existence of Different μ Receptor Subtypes in Different Tissues",
abstract = "A series of β-funaltrexamine (2, β-FNA) analogues (3-14) were synthesized that contain a variety of electrophilic groups attached at the 6/3-position of the opiate. The opioid agonist and antagonist activities of these ligands were evaluated in the guinea pig ileum (GPI) and mouse vas deferens (MVD) in vitro assays. Several of the compounds behaved like β-FNA in that they exhibited reversible agonist activity at k opioid receptors and irreversible antagonist activity at p opioid receptors. The rank order of irreversible antagonism for a series of related Michael acceptors did not parallel their intrinsic chemical reactivity, confirming that the degree of covalent binding is in part dependent on the spatial disposition of the electrophilic center relative to the receptor nucleophile (secondary recognition). The maleimidoacetamide 8 behaved very differently from β-FNA in that it exhibited considerably greater irreversible μ antagonism in MVD relative to the p blockage in the GPI. This suggests that different proportions of p receptor subtypes exist in the two tissues. Several of the agents tested, including some nonreactive control compounds, displayed an unusual type of persistent k agonist activity in the GPI. This activity, which was reversed by addition of naloxone, reappeared upon washing. Receptor models have been presented to explain this effect. A few of the reactive ligands displayed a true nonreversible k agonist activity, suggesting a covalent association with the receptor. Of note in this regard was the propiolamide 6, which appeared to be an irreversible mixed agonist-antagonist at k and μ receptors.",
author = "Sayre, {L. M.} and Larson, {D. L.} and Takemori, {A. E.} and Portoghese, {Philip S}",
year = "1984",
month = "1",
day = "1",
doi = "10.1021/jm00376a018",
language = "English (US)",
volume = "27",
pages = "1325--1335",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "10",

}

TY - JOUR

T1 - Design and Synthesis of Naltrexone-Derived Affinity Labels with Nonequilibrium Opioid Agonist and Antagonist Activities. Evidence for the Existence of Different μ Receptor Subtypes in Different Tissues

AU - Sayre, L. M.

AU - Larson, D. L.

AU - Takemori, A. E.

AU - Portoghese, Philip S

PY - 1984/1/1

Y1 - 1984/1/1

N2 - A series of β-funaltrexamine (2, β-FNA) analogues (3-14) were synthesized that contain a variety of electrophilic groups attached at the 6/3-position of the opiate. The opioid agonist and antagonist activities of these ligands were evaluated in the guinea pig ileum (GPI) and mouse vas deferens (MVD) in vitro assays. Several of the compounds behaved like β-FNA in that they exhibited reversible agonist activity at k opioid receptors and irreversible antagonist activity at p opioid receptors. The rank order of irreversible antagonism for a series of related Michael acceptors did not parallel their intrinsic chemical reactivity, confirming that the degree of covalent binding is in part dependent on the spatial disposition of the electrophilic center relative to the receptor nucleophile (secondary recognition). The maleimidoacetamide 8 behaved very differently from β-FNA in that it exhibited considerably greater irreversible μ antagonism in MVD relative to the p blockage in the GPI. This suggests that different proportions of p receptor subtypes exist in the two tissues. Several of the agents tested, including some nonreactive control compounds, displayed an unusual type of persistent k agonist activity in the GPI. This activity, which was reversed by addition of naloxone, reappeared upon washing. Receptor models have been presented to explain this effect. A few of the reactive ligands displayed a true nonreversible k agonist activity, suggesting a covalent association with the receptor. Of note in this regard was the propiolamide 6, which appeared to be an irreversible mixed agonist-antagonist at k and μ receptors.

AB - A series of β-funaltrexamine (2, β-FNA) analogues (3-14) were synthesized that contain a variety of electrophilic groups attached at the 6/3-position of the opiate. The opioid agonist and antagonist activities of these ligands were evaluated in the guinea pig ileum (GPI) and mouse vas deferens (MVD) in vitro assays. Several of the compounds behaved like β-FNA in that they exhibited reversible agonist activity at k opioid receptors and irreversible antagonist activity at p opioid receptors. The rank order of irreversible antagonism for a series of related Michael acceptors did not parallel their intrinsic chemical reactivity, confirming that the degree of covalent binding is in part dependent on the spatial disposition of the electrophilic center relative to the receptor nucleophile (secondary recognition). The maleimidoacetamide 8 behaved very differently from β-FNA in that it exhibited considerably greater irreversible μ antagonism in MVD relative to the p blockage in the GPI. This suggests that different proportions of p receptor subtypes exist in the two tissues. Several of the agents tested, including some nonreactive control compounds, displayed an unusual type of persistent k agonist activity in the GPI. This activity, which was reversed by addition of naloxone, reappeared upon washing. Receptor models have been presented to explain this effect. A few of the reactive ligands displayed a true nonreversible k agonist activity, suggesting a covalent association with the receptor. Of note in this regard was the propiolamide 6, which appeared to be an irreversible mixed agonist-antagonist at k and μ receptors.

UR - http://www.scopus.com/inward/record.url?scp=0021172139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021172139&partnerID=8YFLogxK

U2 - 10.1021/jm00376a018

DO - 10.1021/jm00376a018

M3 - Article

VL - 27

SP - 1325

EP - 1335

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 10

ER -